Table 2.
Median | (Q1, Q3) | (5%, 95%) | N | % CD19 | (Q1, Q3) | |
% CD45 | 5 | (3, 8) | (2, 16) | 299 | ||
CD3:CD19 | 0.4 | (0.2, 0.7) | (0.1, 1.6) | 289 | ||
B cell antigens | ||||||
CD19 | 68 | (49, 80) | (14, 91) | 302 | ||
CD20 | 68 | (51, 80) | (11, 91) | 296 | 97.8 | (92.7, 105.5) |
CD22 | 56 | (35, 73) | (16, 89) | 274 | 86.3 | (69, 97.7) |
FMC7 | 40 | (20, 60) | (6, 79) | 278 | 61.4 | (39.5, 82) |
CD23 | 28 | (17, 41) | (5, 58) | 278 | 45.9 | (29.3, 62.3) |
CD10 | 17 | (6, 38) | (2, 69) | 296 | 29.8 | (13.7, 55.8) |
CD38+CD19+ | 59 | (40, 72) | (9, 89) | 289 | 92.6 | (82.3, 98.1) |
CD5+CD19+ | 7 | (3, 13) | (1, 25) | 296 | 11.8 | (6.3, 21.6) |
Kappa+ | 42 | (30, 53) | (7, 72) | 299 | 64 | (53.4, 77.5) |
Lambda+ | 31 | (20, 41) | (5, 56) | 300 | 46.6 | (38.2, 60.1) |
Kappa:lambda | 1.3 | (1.1, 1.6) | (1, 2.3) | 298 | ||
T cell antigens | ||||||
CD3 | 27 | (19, 39) | (10, 53) | 291 | ||
CD4 | 51 | (35, 67) | (14, 82) | 288 | ||
CD8 | 10 | (6, 18) | (2, 35) | 288 | ||
CD5 | 20 | (11, 30) | (5, 52) | 296 | ||
CD2 | 30 | (18, 41) | (8, 63) | 238 | ||
CD7 | 24 | (15, 35) | (6, 54) | 239 | ||
CD16+CD3+ | 1 | (0, 2) | (0, 6) | 229 | ||
CD56+CD3+ | 2 | (1, 3) | (0, 8) | 231 | ||
CD57+CD3+ | 6 | (3, 10) | (1, 23.6) | 229 | ||
CD4:CD8 | 4.5 | (3, 7.2) | (1.4, 14.5) | 288 | ||
NK cell antigens | ||||||
CD16+CD3− | 1 | (0, 3) | (0, 10) | 231 | ||
CD56+CD3− | 3 | (1, 5) | (0, 11.1) | 230 | ||
CD57+CD3− | 0 | (0, 1) | (0, 2) | 229 |
NK, natural killer.